Kenya's ability to diagnose, treat MDR-TB questioned after mismanagement of patient's case

"The Kenyan government's recent failure to adequately treat a patient with extensively drug-resistant tuberculosis (XDR-TB) has some civil society organizations questioning whether the country's TB program is equipped to diagnose and treat such patients," PlusNews reports. "The government admits the TB program in Kenya has not been adequately funded despite the country's big TB burden," PlusNews writes, adding, "Kenya ranks 13th on the list of 22 high-burden TB countries in the world and has the fifth-highest burden in Africa."

"The resources that are available ... cannot cope with the burden of the disease as it is today," Joseph Sitienei, director of the National Leprosy and TB Control Programme, told PlusNews, the news service writes. "Another major challenge is that TB patients either report late to health facilities for diagnosis or default on their treatment, increasing their chances of developing drug-resistant TB," the news service adds. "There are more than 500 known cases of [multi-drug resistant TB (MDR-TB)] in Kenya, and only 230 of these are on treatment, but activists warn that more cases could be going undetected," PlusNews notes (2/28).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
WHO reports alarming rise in tuberculosis cases in 2023